Published in Blood on July 12, 2005
Platelet glycoprotein Ibalpha forms catch bonds with human WT vWF but not with type 2B von Willebrand disease vWF. J Clin Invest (2008) 2.43
Single domain antibodies: promising experimental and therapeutic tools in infection and immunity. Med Microbiol Immunol (2009) 1.94
Pathogenesis of thrombotic microangiopathies. Annu Rev Pathol (2008) 1.69
Shear stress-induced unfolding of VWF accelerates oxidation of key methionine residues in the A1A2A3 region. Blood (2011) 1.66
Platelet adhesion under flow. Microcirculation (2009) 1.31
The rate of hemolysis in sickle cell disease correlates with the quantity of active von Willebrand factor in the plasma. Blood (2011) 1.24
Increased ADAMTS-13 proteolytic activity in rat hepatic stellate cells upon activation in vitro and in vivo. J Thromb Haemost (2006) 1.22
Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD. Blood (2010) 1.05
Severe dengue is associated with consumption of von Willebrand factor and its cleaving enzyme ADAMTS-13. PLoS Negl Trop Dis (2012) 0.94
Nanobodies as novel agents for disease diagnosis and therapy. Int J Nanomedicine (2013) 0.93
Perils, problems, and progress in laboratory diagnosis of von Willebrand disease. Semin Thromb Hemost (2013) 0.93
von Willebrand factor: at the crossroads of bleeding and thrombosis. Int J Hematol (2012) 0.88
Cleavage of von Willebrand factor by granzyme M destroys its factor VIII binding capacity. PLoS One (2011) 0.87
The interaction between factor H and Von Willebrand factor. PLoS One (2013) 0.82
No increase in bleeding identified in type 1 VWD subjects with D1472H sequence variation. Blood (2013) 0.81
Variable content of von Willebrand factor mutant monomer drives the phenotypic variability in a family with von Willebrand disease. Blood (2015) 0.79
Proteolytic processing of von Willebrand factor by adamts13 and leukocyte proteases. Mediterr J Hematol Infect Dis (2013) 0.77
Endothelial activation, haemostasis and thrombosis biomarkers in Ugandan children with severe malaria participating in a clinical trial. Malar J (2016) 0.76
Increased active von Willebrand factor during disease development in the aging diabetic patient population. Age (Dordr) (2011) 0.75
At least type VWD2B is a discrete variant of VWD, isn't it? Blood (2009) 0.75
Challenges for Australia's Bio/Nanopharma Policies: trade deals, public goods and reference pricing in sustainable industrial renewal. Aust New Zealand Health Policy (2007) 0.75
Type 2B von Willebrand disease with or without large multimers: A distinction of the two sides of the disorder is long overdue. PLoS One (2017) 0.75
Platelet dysfunction contributes to bleeding complications in patients with probable leptospirosis. PLoS Negl Trop Dis (2017) 0.75
Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum (2002) 5.12
LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron (2004) 4.29
Structures of glycoprotein Ibalpha and its complex with von Willebrand factor A1 domain. Science (2002) 4.15
Prolonged fluid shear stress induces a distinct set of endothelial cell genes, most specifically lung Krüppel-like factor (KLF2). Blood (2002) 3.38
Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. Crit Care Med (2012) 2.51
Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies. Proc Natl Acad Sci U S A (2006) 2.51
Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol (2009) 2.37
Clearance of amyloid-beta by circulating lipoprotein receptors. Nat Med (2007) 2.32
Time course of organ dysfunction in thrombotic microangiopathy patients receiving either plasma perfusion or plasma exchange. Crit Care Med (2006) 2.21
Plasmin cleavage of von Willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy. Circulation (2014) 2.16
Beta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. Blood (2010) 2.04
Association between thrombotic microangiopathy and reduced ADAMTS13 activity in malignant hypertension. Hypertension (2008) 1.95
β-radiation reduces the reactivity of extracellular matrix proteins in intravascular brachytherapy (IVBT), resulting in decreased platelet adhesion. Int J Cardiol (2010) 1.91
Platelet activation by oxidized low density lipoprotein is mediated by CD36 and scavenger receptor-A. Arterioscler Thromb Vasc Biol (2007) 1.85
Antiphospholipid antibodies promote leukocyte-endothelial cell adhesion and thrombosis in mice by antagonizing eNOS via β2GPI and apoER2. J Clin Invest (2010) 1.77
β₂-glycoprotein I: a novel component of innate immunity. Blood (2011) 1.75
Macrophages contribute to the cellular uptake of von Willebrand factor and factor VIII in vivo. Blood (2008) 1.72
Molecular imaging of activated von Willebrand factor to detect high-risk atherosclerotic phenotype. JACC Cardiovasc Imaging (2010) 1.71
Identification of coagulation factor XI as a ligand for platelet apolipoprotein E receptor 2 (ApoER2). Arterioscler Thromb Vasc Biol (2009) 1.64
Factor VIII half-life and clinical phenotype of severe hemophilia A. Haematologica (2005) 1.63
Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs. Blood (2011) 1.59
New class of monoclonal antibodies against severe influenza: prophylactic and therapeutic efficacy in ferrets. PLoS One (2010) 1.59
The glycoprotein Ib-IX-V complex contributes to tissue factor-independent thrombin generation by recombinant factor VIIa on the activated platelet surface. Blood (2008) 1.59
Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation. J Clin Invest (2008) 1.59
Collagens are functional, high affinity ligands for the inhibitory immune receptor LAIR-1. J Exp Med (2006) 1.56
Cell-collagen interactions: the use of peptide Toolkits to investigate collagen-receptor interactions. Biochem Soc Trans (2008) 1.56
Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. Blood (2008) 1.54
Accelerated uptake of VWF/platelet complexes in macrophages contributes to VWD type 2B-associated thrombocytopenia. Blood (2013) 1.51
A novel binding site for ADAMTS13 constitutively exposed on the surface of globular VWF. Blood (2009) 1.51
Factor VIII accelerates proteolytic cleavage of von Willebrand factor by ADAMTS13. Proc Natl Acad Sci U S A (2008) 1.51
Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis. Arthritis Rheum (2006) 1.50
Preferential HLA-DRB1*11-dependent presentation of CUB2-derived peptides by ADAMTS13-pulsed dendritic cells. Blood (2013) 1.49
Staphylococcal superantigen-like 5 binds PSGL-1 and inhibits P-selectin-mediated neutrophil rolling. Blood (2007) 1.47
Elevated levels of D-dimer and fragment 1+2 upon central venous catheter insertion and factor V Leiden predict subclavian vein thrombosis. Haematologica (2005) 1.47
The macrophage mannose receptor promotes uptake of ADAMTS13 by dendritic cells. Blood (2012) 1.46
Thrombocytopenia and release of activated von Willebrand Factor during early Plasmodium falciparum malaria. J Infect Dis (2007) 1.42
The spacer domain of ADAMTS13 contains a major binding site for antibodies in patients with thrombotic thrombocytopenic purpura. Thromb Haemost (2005) 1.39
Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. Blood (2013) 1.36
Shielding of the A1 domain by the D'D3 domains of von Willebrand factor modulates its interaction with platelet glycoprotein Ib-IX-V. J Biol Chem (2005) 1.34
Cladribine therapy for systemic mastocytosis. Blood (2003) 1.34
Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience. PLoS One (2010) 1.33
Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood (2005) 1.32
F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. Blood (2012) 1.31
Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease. Blood (2004) 1.30
Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change. Blood (2005) 1.29
Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology (2006) 1.28
An autoantibody epitope comprising residues R660, Y661, and Y665 in the ADAMTS13 spacer domain identifies a binding site for the A2 domain of VWF. Blood (2009) 1.27
A single high-affinity binding site for von Willebrand factor in collagen III, identified using synthetic triple-helical peptides. Blood (2006) 1.27
ADAMTS13 deficiency with elevated levels of ultra-large and active von Willebrand factor in P. falciparum and P. vivax malaria. Am J Trop Med Hyg (2009) 1.27
The rate of hemolysis in sickle cell disease correlates with the quantity of active von Willebrand factor in the plasma. Blood (2011) 1.24
P-selectin glycoprotein ligand 1 and beta2-integrins cooperate in the adhesion of leukocytes to von Willebrand factor. Blood (2006) 1.24
beta2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood (2004) 1.23
C-reactive protein is a risk indicator for atrial fibrillation after myocardial revascularization. Ann Thorac Surg (2005) 1.23
An experimental model to study the in vivo survival of von Willebrand factor. Basic aspects and application to the R1205H mutation. J Biol Chem (2003) 1.21
Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement. Medicine (Baltimore) (2004) 1.21
Dimers of beta 2-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2'. J Biol Chem (2003) 1.20
VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood (2006) 1.20
IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood (2004) 1.19
Association of polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating RAGE levels. J Clin Endocrinol Metab (2009) 1.17
Synergism between platelet collagen receptors defined using receptor-specific collagen-mimetic peptide substrata in flowing blood. Blood (2010) 1.17
FDG PET/CT for the detection of bone marrow involvement in diffuse large B-cell lymphoma: systematic review and meta-analysis. Eur J Nucl Med Mol Imaging (2013) 1.17
Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood (2010) 1.16
Mapping the collagen-binding site in the von Willebrand factor-A3 domain. J Biol Chem (2003) 1.16
The presence of active von Willebrand factor under various pathological conditions. Curr Opin Hematol (2007) 1.16
Apolipoprotein E receptor 2 is involved in the thrombotic complications in a murine model of the antiphospholipid syndrome. Blood (2010) 1.15
Amino acid regions 572-579 and 657-666 of the spacer domain of ADAMTS13 provide a common antigenic core required for binding of antibodies in patients with acquired TTP. Thromb Haemost (2006) 1.13
Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience. Haematologica (2012) 1.13
Staphylococcus aureus protein A binding to von Willebrand factor A1 domain is mediated by conserved IgG binding regions. FEBS J (2006) 1.13
Glycation induces formation of amyloid cross-beta structure in albumin. J Biol Chem (2003) 1.12
Whole-body MRI, including diffusion-weighted imaging, for the initial staging of malignant lymphoma: comparison to computed tomography. Invest Radiol (2009) 1.11
Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood (2004) 1.10
Newly diagnosed lymphoma: initial results with whole-body T1-weighted, STIR, and diffusion-weighted MRI compared with 18F-FDG PET/CT. AJR Am J Roentgenol (2011) 1.07
The soluble leukocyte-associated Ig-like receptor (LAIR)-2 antagonizes the collagen/LAIR-1 inhibitory immune interaction. J Immunol (2008) 1.07
Altered thrombus formation in von Willebrand factor-deficient mice expressing von Willebrand factor variants with defective binding to collagen or GPIIbIIIa. Blood (2008) 1.05
Circulating biomarkers for predicting cardiovascular disease risk; a systematic review and comprehensive overview of meta-analyses. PLoS One (2013) 1.05
Plasma protein beta-2-glycoprotein 1 mediates interaction between the anti-tumor monoclonal antibody 3G4 and anionic phospholipids on endothelial cells. J Biol Chem (2006) 1.05
Thrombocytopenia in early malaria is associated with GP1b shedding in absence of systemic platelet activation and consumptive coagulopathy. Br J Haematol (2010) 1.04
LDL-receptor-related protein regulates beta2-integrin-mediated leukocyte adhesion. Blood (2004) 1.04
Cancer awareness in atypical thrombotic microangiopathies. Oncologist (2009) 1.03
Haemostatic abnormalities in patients with liver disease. J Hepatol (2002) 1.02
Correlation between antiphospholipid antibodies that recognize domain I of beta2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5. Blood (2006) 1.02
Residues Arg568 and Phe592 contribute to an antigenic surface for anti-ADAMTS13 antibodies in the spacer domain. Haematologica (2011) 1.02
Restoration of plasma von Willebrand factor deficiency is sufficient to correct thrombus formation after gene therapy for severe von Willebrand disease. Arterioscler Thromb Vasc Biol (2008) 1.02
Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura. Blood (2012) 1.01
Thrombospondin-1 mediates platelet adhesion at high shear via glycoprotein Ib (GPIb): an alternative/backup mechanism to von Willebrand factor. FASEB J (2003) 1.01